共 94 条
[1]
Kaukonen KM(2014)Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012 JAMA 311 1308-16
[2]
Bailey M(2015)Augmented renal clearance, low beta-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study Int J Antimicrob Agents 45 385-92
[3]
Suzuki S(2011)Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams Crit Care 15 R206-509
[4]
Pilcher D(2014)Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions Lancet Infect Dis 14 498-83
[5]
Bellomo R(2014)DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58 1072-10
[6]
Huttner A(1998)Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1-51
[7]
Von Dach E(2008)Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections Int J Antimicrob Agents 31 345-30
[8]
Renzoni A(2007)Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections Antimicrob Agents Chemother 51 1725-53
[9]
Huttner BD(2015)Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development Semin Respir Crit Care Med 36 136-6
[10]
Affaticati M(2016)Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis Int J Antimicrob Agents 48 542-48